# Conexeu Sciences Inc.: financial statements, quarterly

CNXU · Nasdaq · CIK 2066836 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Oct 31

Pages: [Overview](/companies/cnxu.md) · [Financials](/companies/cnxu/financials.md) · [Filings](/companies/cnxu/filings.md) · [Insiders](/companies/cnxu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cnxu/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Research and development | $k | [42.5](/filings/0001062993-26-003207.md) | [135](/filings/0001062993-26-004935.md) | [66.6](/filings/0001062993-26-003207.md) | [270](/filings/0001062993-26-004935.md) |
| Operating income | $k | [(457)](/filings/0001062993-26-003207.md) | [(1,298)](/filings/0001062993-26-004935.md) | [(2,380)](/filings/0001062993-26-003207.md) | [(7,688)](/filings/0001062993-26-004935.md) |
| Interest expense | $k | [1.4](/filings/0001062993-26-003207.md) | [(0.0)](/filings/0001062993-26-004935.md) | [0.0](/filings/0001062993-26-003207.md) | [0.0](/filings/0001062993-26-004935.md) |
| Income tax | $k | [0.0](/filings/0001062993-26-003207.md) | [0.0](/filings/0001062993-26-004935.md) | [0.0](/filings/0001062993-26-003207.md) | [0.0](/filings/0001062993-26-004935.md) |
| Net income | $k | [(458)](/filings/0001062993-26-003207.md) | [(1,299)](/filings/0001062993-26-004935.md) | [(2,304)](/filings/0001062993-26-003207.md) | [(7,726)](/filings/0001062993-26-004935.md) |
| Diluted EPS | $ per share | [(0.05)](/filings/0001062993-26-003207.md) | [(0.09)](/filings/0001062993-26-004935.md) | [(0.11)](/filings/0001062993-26-003207.md) | [(0.29)](/filings/0001062993-26-004935.md) |
| Basic EPS | $ per share | [(0.05)](/filings/0001062993-26-003207.md) | [(0.09)](/filings/0001062993-26-004935.md) | [(0.11)](/filings/0001062993-26-003207.md) | [(0.29)](/filings/0001062993-26-004935.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-10-31) | period not labelled (2025-02-01) | period not labelled (2025-04-30) | period not labelled (2025-07-31) | period not labelled (2025-10-31) | period not labelled (2026-01-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | not reported | not reported | not reported | not reported | [4,809](/filings/0001062993-26-004935.md) | not reported | [6,848](/filings/0001062993-26-003207.md) | [1,971](/filings/0001062993-26-004935.md) |
| Current assets | $k | not reported | not reported | not reported | not reported | [7,458](/filings/0001062993-26-004935.md) | not reported | [7,914](/filings/0001062993-26-003207.md) | [6,756](/filings/0001062993-26-004935.md) |
| Total assets | $k | not reported | not reported | not reported | not reported | [7,689](/filings/0001062993-26-004935.md) | not reported | [8,200](/filings/0001062993-26-003207.md) | [7,156](/filings/0001062993-26-004935.md) |
| Current liabilities | $k | not reported | not reported | not reported | not reported | [336](/filings/0001062993-26-004935.md) | not reported | not reported | [1,272](/filings/0001062993-26-004935.md) |
| Total liabilities | $k | not reported | not reported | not reported | not reported | [336](/filings/0001062993-26-004935.md) | not reported | [1,003](/filings/0001062993-26-003207.md) | [1,306](/filings/0001062993-26-004935.md) |
| Shareholders' equity | $k | [95.0](/filings/0001062993-26-004935.md) | [570](/filings/0001062993-26-003207.md) | [177](/filings/0001062993-26-004935.md) | [1,655](/filings/0001062993-26-004935.md) | [7,353](/filings/0001062993-26-004935.md) | [6,826](/filings/0001062993-26-003207.md) | [7,196](/filings/0001062993-26-004935.md) | [5,850](/filings/0001062993-26-004935.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2025-07-31) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: |
| Operating cash flow | $k | [(574) d](/filings/0001062993-26-004935.md) | [(6,759) d](/filings/0001062993-26-004935.md) |
| Capital expenditure | $k | [0.4 d](/filings/0001062993-26-004935.md) | [41.4 d](/filings/0001062993-26-004935.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2025-04-30) | period not labelled (2025-07-31) | Q2 FY2026 (2026-04-30) | Q3 FY2026 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.5](/filings/0001062993-26-003207.md) | [14.1](/filings/0001062993-26-004935.md) | [20.6](/filings/0001062993-26-003207.md) | [27.0](/filings/0001062993-26-004935.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 28,206,698 at 2026-09-10, from the cover of the [10-Q filed 2026-09-14](/filings/0001062993-26-004935.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.